ArticleArchives of dermatological research2025
Describing atopic dermatitis in real-world clinical practice: a retrospective health system analysis.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective management of atopic dermatitis (AD) is hindered by gaps in the comprehensive documentation of clinician-observed signs and patient-reported experiences. Our objective was to assess the comprehensiveness of AD documentation in clinical practice. A retrospective analysis of electronic health records from a regional health system (2010-2022, n = 17,053) was conducted. Manual review of 2,193 records confirmed 600 AD patients. Documentation of skin signs, disease burden, and disease progression was evaluated. Narrative descriptions of lesion morphology and location were documented in 76.2% and 92.7% of notes, respectively. Only a minority commented on chronicity (6.2%), signs other than erythema (≤ 25.0%), disease extent (38.2%), or severity (IGA/PGA: 26.8%; EASI: 4.7%). Itch, skin pain, sleep disturbances, and mental health symptoms were reported in 58.7%, 14.5%, 10.2%, and 1.0% of notes, respectively, with numerical rating scales rarely applied. Patient-assessed global severity was recorded in 6.2% of notes, and QoL impact in 3.8%. Documentation of flare frequency, duration, and post-treatment changes was rare. Our findings reveal strikingly incomplete clinical documentation of AD, underscoring the need for a structured approach to better document activity and address true disease burden.
Indexed as
Identifiers
39920465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.